Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.
Toni K ChoueiriAmber C DonahueDavid A BraunBrian I RiniThomas PowlesJohn B A G HaanenJames M G LarkinXinmeng Jasmine MuJie PuRosemary E TeresiAlessandra di PietroPaul B RobbinsRobert J MotzerPublished in: Cancer discovery (2024)
Our findings provide novel insights into the different immunomodulatory mechanisms governing responses in patients treated with avelumab (PD-L1 inhibitor) + axitinib or sunitinib (both VEGF inhibitors), highlighting the contribution of tumor biology to the complexity of the roles and interactions of infiltrating immune cells in response to these treatment regimens.